Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07457307) titled 'Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac' on March 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: NYU Langone Health
Condition:
High-grade Glioma
Intervention:
Device: MR-Linac System
Radiation: Radiation Therapy
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: June 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stu...